The effect of LMWH (Nadroparin) on tumor progression.
Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.
Nagy
Zsuzsanna
Z
Department Clinical Oncology, St. Imre Hospital, Budapest, Hungary.
Turcsik
Vera
V
Blaskó
György
G
D000925:Anticoagulants / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D017762:Nadroparin / Q000627:therapeutic use*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010865:Pilot Projects; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
D000925:Anticoagulants; D017762:Nadroparin; D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D002955:Leucovorin; D005472:Fluorouracil